Scarica l'app Stockscreener
5.38
6.11%
-0.35
Aardvark Therapeutics Inc Borsa (AARD) Ultime notizie
AARD INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
DEADLINE ALERT for HDB, SMPL, and AARD: The Law Offices of - GlobeNewswire
Aardvark Therapeutics, Inc. (AARD) LawsuitInvestors Urged to Contact Levi & Korsinsky Before October 13, 2026 - ACCESS Newswire
2026-08-21 | Faruqi & Faruqi, LLP Urges Aardvark Therapeutics (NASDAQ: AARD) Investors to Seek Counsel Before October 13, 2026 Lead Plaintiff Deadline in the Securities Class Action | NDAQ:AARD | Press Release - Stockhouse
Aardvark Therapeutics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsAARD - WBOC TV
Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - Sahm
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law - Business Wire
Aardvark Therapeutics Lawsuit Alleges Investors Were Misled Before Sharp AARD Stock Drops - TipRanks
LAWSUIT ALERT: Investors who lost over $100,000 with Aardvark Therapeutics, Inc. (NASDAQ: AARD) between February 2025 and May 2026, should contact the Shareholders Foundation - Morningstar
AARD Stock Plummets After Hours As Cardiac Safety Concerns Trigger FDA Hold On Late-stage Program - Stocktwits
AARD Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aardvark Therapeutics Securities LawsuitContact SueWallSt - Morningstar
Levi & Korsinsky Reminds Aardvark Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 13, 2026AARD - Business Wire
Aardvark Therapeutics Faces Securities Class Action Lawsuit - Intellectia AI
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and DirectorsAARD - PR Newswire
AARDVARK THERAPEUTICS, INC. (AARD) SHAREHOLDER ALERT - GlobeNewswire
Aardvark (AARD) Quarterly Figures: EPS Falls Short of Its Estimate in the Current Update; Share Move: The Stock Records a 9.85% Increase in the Latest SessionEarnings Power Value - vinanet.vn
symbol__ Stock Quote Price and Forecast - CNN
Lost Money on Aardvark Therapeutics, Inc. (AARD)? Urged to Join Class Action Before October 13, 2026Contact Levi & Korsinsky - ACCESS Newswire
Lawsuit ALERT: Investors who lost money with shares of Aardvark Therapeutics, Inc. (NASDAQ: AARD) - openPR.com
AARD Class Action ReminderRobbins LLP Reminds Investors - GlobeNewswire
Securities Fraud Investigation Into Aardvark Therapeutics, Inc. (AARD) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - The AI Journal
Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit - TMX Newsfile
AARD Shareholder Alert: October 13, 2026 Lead Plaintiff Deadline in Aardvark Therapeutics, Inc. Securities Class ActionContact Levi & Korsinsky - PR Newswire
ROSEN, A RESPECTED AND LEADING FIRM, Encourages Aardvark Therapeutics, Inc. Investors to Secure ... - Caledonian Record
ROSEN, A RESPECTED AND LEADING FIRM, Encourages Aardvark - GlobeNewswire
AARD INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Aardvark (AARD) Results at a Glance: The Bottom-Line Figure Trails Its Comparison at the Close; Market Read: The Stock Records a 9.27% Decrease in the Latest SessionGuidance vs Actual - vinanet.vn
Bronstein, Gewirtz & Grossman LLC Urges Aardvark - GlobeNewswire
Kaplan Fox Encourages Investors of Aardvark Therapeutics, Inc. (N - The National Law Review
Shareholders sue Aardvark Therapeutics over all... - Pluang
AARDVARK THERAPEUTICS, INC. (AARD) INVESTOR ALERT Investors With Large Losses in Aardvark Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights - TMX Newsfile
AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Class Action - PR Newswire
AARD Investor Notice: Hagens Berman Alerts Investors in - GlobeNewswire
Aardvark Therapeutics Shareholders Approve Governance and Incentives - TipRanks
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
AARD Stockholder Notice: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Aardvark Therapeutics, Inc. - Business Wire
Class action filed against Aardvark Therapeutics over safety issues and FDA clinical hold on drug trial. - Pluang
Rosen Law Firm Urges Aardvark Therapeutics, Inc. (NASDAQ: AARD) Stockholders to Contact the Firm for Information About Their Rights - Business Wire
AARD INVESTOR ALERT: Class Action Lawsuit Filed on Behalf - GlobeNewswire
Aardvark Therapeutics held annual shareholder meeting - Bitget
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
AARD SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Aardvark ( - GuruFocus
AARD SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026 - Business Wire
Analysts Offer Insights on NA Companies: Nakamoto Inc (NAKA) and Aardvark Therapeutics, Inc. (AARD) - The Globe and Mail
BofA Securities Maintains Aardvark Therapeutics(AARD.US) With Sell Rating - Moomoo
Aardvark Therapeutics (NASDAQ:AARD) Raised to "Sell" at Wall Street Zen - MarketBeat
Stockholder Alert: Robbins LLP Informs Investors of the Aardvark Therapeutics, Inc. (UWM) Class Action - lincolnjournal.com
Aardvark Therapeutics, Inc. Common Stock (NASDAQ: AARD) Stock Price, News & Analysis - Kalkine
Aardvark Therapeutics Company Profile & Introduction - Moomoo
Aardvark Therapeutics (AARD) Retreats 2.4%: Stock Holds Above Key $6.09 SupportTriple Top - Vinanet
Aardvark Therapeutics (AARD) Slips 2.13% to $6.43 as Traders Eye Key Support at $6.11Total Put Call - vinanet.vn
Layoff Tracker: Sanofi cuts 229 Blueprint Medicines employees - BioSpace
AI Risk and Regulation: How Aardvark Therapeutics’ Use of Artificial Intelligence Could Expose It to Compliance, Cybersecurity, and Competitiveness Challenges - TipRanks
Aardvark Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Morgan Stanley Maintains Aardvark Therapeutics(AARD.US) With Sell Rating, Maintains Target Price $3 - Moomoo
Why is Aardvark Therapeutics stock surging today? By Investing.com - Investing.com Canada
Why is Aardvark Therapeutics stock surging today? - Investing.com
Form 8K Aardvark Therapeutics Inc For: 11 August By Investing.com - Investing.com India
Aardvark Therapeutics Q2 EPS of $(0.66) beats $(0.91) estimate - scanx.trade
Aardvark Therapeutics (AARD) faces ARD-101 clinical hold but retains $73.9M cash - Stock Titan
Aardvark Therapeutics (NASDAQ:AARD) Releases Quarterly Earnings Results, Beats Expectations By $0.21 EPS - MarketBeat
Aardvark Therapeut reports Q2 2026 results — $73.9M cash; net loss $14.4M - TradingView
Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Aardvark Therapeutics, Inc. Q2 2026: Net loss $14.4M, EPS $(0.66) — 10-Q Summary - TradingView
Aardvark Reports $14.4 Million Q2 Net Loss as ARD-101 Hold Continues - Quiver Quantitative
AARD: Q2 2026 net loss was $14.4M; cash reserves support operations into late 2027 - TradingView
Aardvark Therapeutics Q2 operating expenses fall on paused ARD-101 clinical trials and workforce reduction - TradingView
Aardvark Therapeutics Reports Q2 2026 Results, Updates ARD-101 PWS Program and FDA Discussions - Quiver Quantitative
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):